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Abstract
Objectives: Hepatectomy patients are known to be at significant risk for venous thromboembolism
(VTE), but previous studies have not differentiated pre- versus post-discharge events. This study was
designed to evaluate the timing, rate and predictors of pre- (‘early’) versus post-discharge (‘late’) VTE.
Methods: All patients undergoing elective hepatectomy during 2005–2010 and recorded in the American
College of Surgeons National Surgical Quality Improvement Program participant use file were identified.
Perioperative factors associated with 30-day rates of early and late VTE were analysed.
Results: A total of 7621 patients underwent 4553 (59.7%) partial, 802 (10.5%) left, 1494 (19.6%) right
and 772 (10.1%) extended hepatectomies. Event rates were 1.9% for deep venous thrombosis, 1.2% for
pulmonary embolus and 2.8% for VTE. Of instances of VTE, 28.6% occurred post-discharge. The median
time of presentation of late VTE was postoperative day 14. Multivariate analysis determined that early VTE
was associated with age 75 years [odds ratio (OR) 1.92, P = 0.007], male gender (OR 1.87, P = 0.002),
intraoperative transfusion (OR 2.49, P < 0.001), operative time of >240 min (OR 2.28, P < 0.001), organ
space infection (OSI) (OR 2.60, P < 0.001), and return to operating room (ROR) (OR 3.25, P < 0.001). Late
VTE was associated with operative time of >240 min (OR 2.35, P = 0.008), OSI (OR 3.78, P < 0.001) and
ROR (OR 2.84, P = 0.011).
Conclusions: Late VTE events occur in patients with clearly identifiable intraoperative and postoperative
risk factors. This provides a rationale for the selective use of post-discharge VTE chemoprophylaxis in
high-risk patients.
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Introduction
Until recently, many liver surgeons have withheld postoperative
venous thromboembolism (VTE) chemoprophylaxis due to a per-
ceived increased risk for perioperative bleeding.1 This practice has
continued despite increasing evidence over the past two decades
demonstrating the benefits of incorporating postoperative VTE
chemoprophylaxis within the standard of care in major abdomi-
nal surgery, especially for cancer patients.2–8 The historical fear
of bleeding was supported by the popular belief that transient
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postoperative liver insufficiency, especially after major and
extended hepatectomies, would make the patient’s blood ‘thin’
and thus resistant to the VTE commonly seen in general surgery
patients. In a previous study, the current authors disproved that
paradigm by demonstrating that hepatectomy patients were at
significantly increased risk for postoperative VTE, especially those
who had undergone major hepatectomy or longer operations and
those who suffered postoperative organ space infection (OSI) or
bile leaks.1
Most guidelines for VTE prevention recommend the use of
postoperative chemoprophylaxis for major abdominal surgery,
especially in cancerpatients,as long as the risk for bleedingdoesnot
outweigh that for VTE.5,9,10 Several studies have shown the benefit
of longer-term, post-discharge chemoprophylaxis in high-risk
patients.9–12 However, prolonged VTE chemoprophylaxis has sig-
nificant implications, including prescription costs, patient discom-
fort and bleeding risk.10 The optimal strategy for the prevention of
late VTE would, therefore, be to focus post-discharge chemo-
prophylaxis only on patients who are at high risk for late VTE. As
postoperative chemoprophylaxis is still not uniformly given to all
hepatectomy patients, asking liver surgeons to give even longer
prescriptions beyond discharge seems impractical without proof
that high-risk patients do exist. To appropriately influence practice
patterns, it is first necessary to establish evidence that post-
dischargeVTE represents a significant proportion of all postopera-
tive VTE. Secondly, a way to identify high-risk patients who might
benefit from extended chemoprophylaxis must be established
rather than prescribing it to all hepatectomy patients.
Amulti-institution national database, such as that of theAmeri-
can College of Surgeons National Surgical Quality Improvement
Program (ACS-NSQIP), facilitates the analysis of risk factors asso-
ciated withmajor surgical complications simply because its scale is
much greater than that of smaller institutional databases, especially
for hepatobiliary surgery.13 The ACS-NSQIP allows surgeons to
look beyond the bias and small-number limitations of single-
institution databases to study surgical morbidity and mortality
event rates and risk factors on a broader scale, which can more
accurately describe overall trends and identify areas in need of
surgical quality improvement.14
The hypothesis of this study was that a certain subset of post-
hepatectomy patients are at risk for post-discharge VTE and that
certain clinical factors might help surgeons identify these
patients at high risk for late VTE. To test this hypothesis, this
study was designed to evaluate the rates and timing of, and
risk factors for, pre-discharge versus post-discharge VTE after
hepatectomy.
Materials and methods
Data acquisition, patients and definitions
All hepatectomy procedures carried out in 2005–2010 and
recorded in the ACS-NSQIP participant use file (PUF) were iden-
tified. Patients who underwent emergency operations and wedge
resections [current procedural terminology (CPT) code 47100]
were excluded; all remaining patients were included for analysis.
The extent of liver resection was classified according to the
primary CPT code and included in order of increasing magnitude
partial (CPT 47120), left (CPT 47125), right (CPT 47130) and
extended (CPT 47122) hepatectomies. Risk factors for pre-
discharge and post-discharge VTE were derived from the analysis
of the full spectrum of NSQIP-collected clinical factors.
The preoperative NSQIP risk factors assessed included age, sex,
race, weight/body mass index (BMI; obesity was defined as BMI of
30 kg/m2), performance status, albumin, haematocrit, platelets,
blood urea nitrogen, creatinine, partial thrombin time, interna-
tional normalized ratio (INR), alkaline phosphatase, aspartate
aminotransferase (AST), bilirubin, white blood cell count,
American Society of Anesthesiologists (ASA) class, smoking,
chronic obstructive pulmonary disease, pneumonia, sepsis, dis-
seminated cancer, diabetes, bleeding disorder, ascites, preopera-
tive chemotherapy, preoperative radiation therapy, preoperative
transfusion, previous operation within 30 days, and preoperative
hospitalization.
Intraoperative variables included operative time, intraoperative
transfusion, extent of hepatectomy, concurrent major operation,
and radiofrequency ablation. Concurrent major operations
included gastrointestinal resection, gastrointestinal anastomosis,
biliary resection/reconstruction, thoracic operation and ventral
hernia repair. Major operations were not considered to include
cholecystectomy, vena caval repair, diaphragm repair, lym-
phadenectomy or diagnostic laparoscopy.
Postoperative metrics included postoperative transfusion,
bleeding transfusion (major transfusion of >4 units of blood
within 72 h after surgery), return to operating room (ROR) within
the same hospitalization, renal insufficiency or failure, respiratory
failure, cardiac arrest, myocardial infarction, postoperative sepsis/
septic shock, surgical site infection, OSI (abscess/biloma), wound
disruption (fascial dehiscence), length of stay (LoS), and mortal-
ity, as standardized and defined by the NSQIP.13 Based on the
limitations intrinsic to NSQIP data, post-hepatectomy mortality
was defined as death within 30 days post-surgery, or death at a
later date if the patient was hospitalized continuously from
surgery to the date of death.
The analysis of post-hepatectomy thrombotic events within 30
days of hepatectomy focused on deep vein thrombosis (DVT),
pulmonary embolism (PE) and the combination of the two.
Venous thromboembolism was defined as a clinically detected
DVT or PE. Patients documented to have both DVT and PE were
labelled only once forVTE. The timing of VTE was compared with
the discharge date and stratified as ‘early’ (pre-discharge) or ‘late’
(post-discharge). The minimum number of patients needed to
treat (NNT) to prevent a clinically apparent VTE event as defined
by NSQIP criteria was estimated for various at-risk populations
based on late VTE rates and hypothetical cohort sizes treated with
extended VTE chemoprophylaxis on the assumption that chemo-
prophylaxis would prevent VTE events. This was calculated using
this formula: 1/(VTE rate, %).
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Statistical analysis
The associations of clinical factors with early and late VTE were
analysed using the chi-squared test or Fisher’s exact test for non-
parametric categorical data and the Mann–Whitney U-test for
non-parametric continuous data. To determine independent asso-
ciations, significant univariate risk factors (i.e. P < 0.05) were
entered into a multivariate logistic regression model. In subse-
quent analyses, the ‘high-risk’VTE group was defined as having at
least one independent risk factor from the multivariate model.
Statistical analyses were performed using IBM spss Statistics 19
(IBM Corp., Armonk, NY, USA). All tests were two-sided. Statis-
tical significance was indicated by a P-value of < 0.05.
Results
Patients and hepatectomies analysed
For the period 2005–2010, a total of 7621 patients who met the
study inclusion criteria were identified. The median age of these
patients was 60 years (range: 17–90 years). A total of 3931 (51.6%)
were female and 5735 (75.3%) were of White European ethnicity.
Liver resections included 4553 (59.7%) partial, 802 (10.5%) left,
1494 (19.6%) right and 772 (10.1%) extended hepatectomies.
Indications for surgery included malignant diagnoses in 6508
(85.4%) patients. There was no difference in VTE rates between
patients with malignant (3.0%) and benign (2.1%) indications
(P = 0.173). Other clinically relevant preoperative, intraoperative
and postoperative factors are described in Table 1.
Rates and timing of post-hepatectomy
thrombotic events
Overall thrombotic events included 91 (1.9%) DVTs, 142 (1.2%)
PEs, and 210 (2.8%) VTEs. Incidences of VTE amounted to 4.4%
in patients undergoing right and extended hepatectomies, and
2.1% in those undergoing left and partial hepatectomies (P <
0.001). Operative time was stratified as >240 min and 240 min;
incidences of VTE amounted to 4.6% in the cohort with longer
operative time and 1.4% in that with shorter operative time. Late
events accounted for 27.5%, 33.0% and 28.6% of all occurrences
of DVT, PE andVTE, respectively (Fig. 1). The median date of any
VTE was postoperative day (PoD) 9 and the median discharge
date was PoD 6 (Fig. 2). Among patients with early VTE, the
median date of VTE was PoD 6 and the median discharge date was
PoD 15. Among patients with late VTE, the median date of VTE
was PoD 14 and the median discharge date was PoD 7.
Factors associated with pre-discharge VTE
Univariate factors associated with early VTE are detailed in
Table 1. Multivariate analysis of these risk factors determined that
preoperative, intraoperative and postoperative risk factors were
independently associated with pre-dischargeVTE (Table 2). These
risk factors included age75 years,male sex, intraoperative trans-
fusion, operative time >240 min, postoperative OSI and ROR (all
P < 0.01). Longer operative time was used as a surrogate for the
magnitude of the operation because of the variability in operative
time for each type of hepatectomy. Organ space infection
occurred in 6.3% of all patients, 9.4% of those undergoing right or
extended hepatectomy, and 5.0% of those receiving partial or left
hepatectomy (P < 0.001). Although the overall rate of early VTE
was 2.0%, patients with OSI or ROR had pre-discharge VTE rates
of 6.9% and 9.8%, respectively (P < 0.001). Patients with early
VTE suffered a 30-day mortality rate of 9.3%, whereas the overall
baseline mortality rate was 2.3% (P < 0.001).
Factors associated with post-discharge VTE and the
number of high-risk patients needed to treat analysis
Univariate factors associated with late VTE are detailed in Table 1.
Multivariate analysis identified independent associations with
post-discharge VTE; these indicated intraoperative and postop-
erative risk factors, but not preoperative variables (Table 2). These
independent risk factors included an operative time of >240 min,
ROR and OSI (all P < 0.02). In patients at high risk for late VTE,
incidences of all VTE, early VTE and late VTE were, respectively,
4.6%, 3.4% and 1.2% in patients in whom surgery lasted
>240 min, 10.0%, 6.9% and 3.1% in patients who experienced an
OSI, and 12.5%, 9.8% and 2.7% in ROR patients. Although the
overall rate of late VTE was 0.8%, patients with an OSI and ROR
patients had post-discharge VTE rates of 3.1% and 2.7%, respec-
tively (P < 0.001).
On the assumption that chemoprophylaxis prevents VTE, if
extended chemoprophylaxis to PoD 30 were to be administered to
all patients with the risk factors of operative time >240 min, OSI
and/or ROR, this would cover 78.3% of patients who experienced
late events and thus imply that 75 patients is the minimum NNT
to prevent one late VTE. Expanding these criteria to include
patients who underwent right or extended hepatectomy might
avoid 88.3% of late events with a minimum NNT of 81 patients.
Tightening the selection criteria to include only patients with
postoperative OSI and ROR improves the minimum NNT to 32
patients, but would theoretically reduce the coverage of patients
with late events to only 36.7%.
Discussion
The aim of the present study was to evaluate the rates and timing
of, and risk factors for, pre- versus post-discharge VTE after hepa-
tectomy and to identify high-risk patients whomight benefit from
chemoprophylaxis against late VTE. This is the first study to iden-
tify distinct risk factors for pre-discharge versus post-discharge
VTE after hepatectomy. Its standardized quality measures and
national scale make the ACS-NSQIP database very suitable for
further study of post-hepatectomy VTE.1 This analysis showed
that late VTE does indeed represent a problem that has impact
after liver surgery as 28.6% of all instances of VTE occurred after
discharge. Although pre-discharge VTE risk factors included
preoperative, intraoperative and postoperative factors, post-
discharge VTE was associated with only intraoperative and post-
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Table 1 Factors associated with no venous thromboembolism (VTE), early VTE and late VTE
Clinical characteristic All patients
(n = 7621)
No VTE
(DVT or PE)
Early (pre-discharge)
VTE
Late (post-discharge)
VTE
Early
versus
none
Late
versus
none
Early
versus
late
n or median % n or median % n or median % n or median % P-value P-value P-value
Patients 7621 100% 7411 97.2% 150 2.1 60 0.8%
Preoperative factors
Age, years, median (range) 60 (17–90) 60 (17–90) 65 (23–90) 62 (26–83) <0.001 0.616 0.066
Age 75 years 894 11.7% 860 11.6% 29 19.3% 5 8.3% 0.004 0.546 0.051
Sex, male 3690 48.4% 3556 48.0% 98 65.3% 36 60.0% <0.001 0.175 0.600
Race, White 5735 75.3% 5561 75.0% 122 81.3% 52 86.7% 0.077 0.038 0.354
Lack of functional independence 148 1.9% 138 1.9% 7 4.7% 3 5.0% 0.013 0.075 1.000
Albumin <4 g/dl 2837 37.2% 2738 36.9% 77 51.3% 22 36.7% <0.001 0.965 0.054
Alkaline phosphatase >93 IU/l 3349 43.9% 3240 43.7% 85 56.7% 24 40.0% 0.002 0.563 0.029
AST 30 IU/l 2947 38.7% 2847 38.4% 73 48.7% 27 45.0% 0.011 0.296 0.631
Haematocrit < 39% 3435 45.1% 3332 45.0% 83 55.3% 20 33.3% 0.011 0.071 0.004
BUN 20 mg/dl 1205 15.8% 1159 15.6% 34 22.7% 12 20.0% 0.019 0.355 0.673
ASA class 3 5074 66.6% 4913 66.3% 120 80.0% 41 68.3% <0.001 0.739 0.071
Intraoperative factors
Operative time, min, median
(range)
220 (7–1029) 218 (7–1029) 298 (100–780) 273 (115–734) <0.001 <0.001 0.112
Operative time >240 min 3283 43.1% 3133 42.3% 110 73.3% 40 66.7% <0.001 <0.001 0.398
Any intraoperative transfusion 1514 26.6% 1431 25.9% 68 57.1% 15 31.3% <0.001 0.397 0.002
RBC 2 units 1207 21.2% 1134 20.5% 61 51.3% 12 25.0% <0.001 0.443 0.002
RBC 4 units 523 9.2% 486 8.8% 30 25.2% 7 14.6% <0.001 0.159 0.135
Extent of hepatectomy <0.001 0.006 0.024
Partial 4553 59.7% 4458 60.2% 64 42.7% 31 51.7%
Left 802 10.5% 787 10.6% 12 8.0% 3 5.0%
Right 1494 19.6% 1433 19.3% 39 26.0% 22 36.7%
Extended 772 10.1% 733 9.9% 35 23.3% 4 6.7%
Partial versus left/right/extended <0.001 0.181 0.237
Right/extended versus left/partial <0.001 0.017 0.432
Right/extended 2266 29.7% 2166 29.2% 74 49.3% 26 43.3%
Left/partial 5355 70.3% 5245 70.8% 76 50.7% 34 56.7%
Biliary resection or anastomosis 364 4.8% 340 4.6% 20 13.3% 4 6.7% <0.001 0.360 0.231
Concurrent major GI or
abdominal case
912 12.0% 867 11.7% 36 24.0% 9 15.0% <0.001 0.419 0.151
Postoperative factors
Any transfusion 494 6.5% 469 6.3% 22 14.7% 3 5.0% <0.001 1.000 0.060
Bleeding transfusion only 46 0.6% 39 0.5% 6 4.0% 1 1.7% <0.001 0.276 0.676
Return to operating room 335 4.4% 293 4.0% 30 20.0% 12 20.0% <0.001 <0.001 1.000
Renal insufficiency/failure 169 2.2% 150 2.0% 16 10.7% 3 5.0% <0.001 0.124 0.288
Any SSI, wound disruption 895 11.7% 828 11.2% 47 31.3% 20 33.3% <0.001 <0.001 0.779
Organ space infection 478 6.3% 430 5.8% 33 22.0% 15 25.0% <0.001 <0.001 0.640
Postoperative LoS, days, median
(range)
6 (1–138) 6 (1–138) 15 (1–117) 7 (3–24) <0.001 0.004 <0.001
Postoperative LoS 7 days 3062 40.2% 2888 39.0% 139 92.7% 35 58.3% <0.001 0.002 <0.001
Death within 30 days 177 2.3% 162 2.2% 14 9.3% 1 1.7% <0.001 1.000 0.072
P-values in bold indicate significance at P < 0.05.
Non-significant factors: year of operation; diabetes; body mass index; smoking; alcohol use; dyspnoea; stroke; pulmonary disease; sodium; white blood cell count; platelet count;
creatinine; partial thrombin time; international normalized ratio; total bilirubin; ascites; varices; pneumonia; steroids; open wound; disseminated cancer; preoperative transfusion; bleeding
disorder; operation in preceding 30 days; chief resident involvement; preoperative chemotherapy within 30 days; radiation therapy within 90 days; preoperative weight loss of >10%;
admission before operation; postoperative re-intubation/ventilator >48 h; cardiac arrest; myocardial infarction; sepsis, and septic shock.
DVT, deep venous thrombosis; PE, pulmonary embolism; AST, aspartate aminotransferase; BUN, blood urea nitrogen; ASA, American Society of Anesthesiologists; RBC, red blood cells;
GI, gastrointestinal; SSI, surgical site infection; LoS, length of stay.
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operative risk factors. Patients with longer operative time, OSI
and/or ROR status were at high risk for late VTE.
Post-discharge VTE is a clinical problem that has been previ-
ously described in studies of patients undergoing abdominal
surgery, although, historically, hepatobiliary operations (the vast
majority of which are carried out for malignant indications) have
been under-represented in these analyses and not specifically
studied.5,9,11 In one prospective observational study of 1238
general surgery patients, 40% of VTE occurred after PoD 21, and
VTE was responsible for almost half of the 30-day deaths in the
study cohort.15 Although postoperative VTE chemoprophylaxis in
the form of low-dose unfractionated heparin or low molecular
weight heparin is a Grade 1B recommendation within the most
recent American College of Chest Physicians (ACCP) guidelines,
issued in 2012, for all moderate- to high-risk (defined by a VTE
rate of 3–6%) general surgery patients undergoing major surgery,
there remains no uniform protocol regarding the length of
therapy.10
Past studies comparing extended-duration 30-day VTE chemo-
prophylaxis with pre-discharge-only chemoprophylaxis generally
showed lowerVTE rates (5.9% versus 13.6%,with a relative risk of
0.44 in a recent meta-analysis) in the extended chemoprophylaxis
arms.11,12,16 This meta-analysis indicated that the number of
patients needed to treat to prevent a single VTE was 13, and thus
the issue of cost-effectiveness raises its head as pharmacologic
costs must be balanced against the morbidity and cost of each
VTE. Currently, high-risk patients undergoing abdominal cancer
surgery are recommended by the ACCP (Grade 1B) to undergo 4
weeks of extended-duration chemoprophylaxis if there is not a
high risk for bleeding.10 Although most surgeons would consider
universal prescription of extended VTE chemoprophylaxis to be
safe (with no increase in bleeding complications in comparison
with in-hospital chemoprophylaxis only),16 the cost of a 1-month
supply of whichever drug is chosen may be quite high, especially
for patients without adequate health insurance coverage. There-
fore, there is a clause in the guidelines which states that patients
who have to bear the financial burden of the extended-duration
chemoprophylaxis may instead choose limited-duration chemo-
prophylaxis.10 However, as postoperative VTE is considered a pre-
ventable nosocomial complication that has both hospital cost
and reimbursement implications, clinicians and administrators
should be encouraged to facilitate the systematic identification
and treatment of high-risk patients.7
The primary analysis of the present study determined that
28.6% of VTE events after liver surgery occurred after discharge.
In current practice, most hepatectomy patients are discharged
relatively quickly, as the median LoS of only 6 days in the overall
national cohort reflects. The median day of any VTE was PoD 9.
These data suggest that it is naïve to assume that all discharged
liver surgery patients are fully ambulatory and free of thrombotic
post-surgical inflammatory issues. This is especially relevant to
patients who have undergone larger resections, in whom physi-
ologic demands to regenerate the liver are higher, leaving them
Figure 1 Post-discharge instances of venous thromboembolism
(VTE) represent 28.6% of all post-hepatectomy occurrences of VTE.
Columns are labelled with the number and percentage of patients in
whom each event occurred. PE, pulmonary embolism; DVT, deep
venous thrombosis
Figure 2 Distribution of dates of (a) discharge after hepatectomy and
(b) venous thromboembolism (VTE). Vertical lines mark the median
dates for each
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with some element of persistent fatigue. Hepatectomies of larger
magnitude are also associated with a higher risk for bile leak, some
instances of which present post-discharge.17 Those patients who
have suffered major bile leaks or have required reoperation for
bleeding or bile leaks would certainly be at high risk for late VTE,
even after meeting hospital discharge criteria.
Another remarkable finding of this analysis that relates to the
association of postoperative complications and VTE events was
the temporal relationship between early or late VTE and discharge
date. Early VTE, which occurred at a median of 6 days postopera-
tively, was associated with discharge at a median of 15 days,
reflecting the impact of VTE and other complications on LoS. By
contrast, late VTE occurred at a median of 14 postoperative days
and was associated with discharge at a median of 7 days post-
surgery. These data indicate that despite meeting discharge crite-
ria, certain hepatectomy patients harbour significant thrombotic
risks. These findings have important implications for extended
VTE chemoprophylaxis, particularly with the more frequent uti-
lization of enhanced recovery after surgery (ERAS) or fast-track
protocols that reduce the LoS after hepatectomy. This will poten-
tially increase the proportion of patients experiencing VTE in the
post-discharge period and will place a greater premium on the
accurate identification of high-risk patients whomay benefit from
post-discharge chemoprophylaxis.
The second focus of the study was to determine if there was a
difference between risk factors for pre-discharge and post-
discharge VTE. A practical aim was to identify high-risk patients
who might benefit from post-discharge chemoprophylaxis. Inter-
estingly, with regard to late VTE, variables related to the extent of
and complications from hepatectomy outweighed all preoperative
variables. This potentially allows for the selection of patients for
extended chemoprophylaxis based on the conduct of the opera-
tion and the course of inpatient recovery. As in-hospital postop-
erative VTE chemoprophylaxis is now within the standard of care
in all general surgery operations including hepatectomies, identi-
fying the risk factors for early VTE is important, but not as clini-
cally useful as selecting patients who would benefit from
chemoprophylaxis beyond discharge. Although it is true that the
overall absolute risk for late VTE among all hepatectomy patients
is low (around 0.8%), in high-risk patients, this risk is three to
four times greater. Thus the NNT of high-risk patients to prevent
a VTE is lower, improving the cost-effectiveness of extended
chemoprophylaxis.
According to the present analysis, the minimum NNT of high-
risk patients to prevent a single late VTE ranges between 33 and 81
depending on the stringency of selection criteria and the desired
yield of late VTE prevention. The validity of these NNT calcula-
tions is dependent on several assumptions, including that postop-
erative chemoprophylaxis from PoD 1 to the date of discharge is
routine and that post-discharge chemoprophylaxis is effec-
tive.11,12,18 An additional point regarding these NNT calculations is
that they are based on symptomatic VTE as captured by the
NSQIP, which explains why these NNT estimates are higher than
those reported in prospective studies in which patients were
screened at 4 weeks to detect asymptomatic VTE.11,12,15,18
As in a previous study conducted by the present group on
postoperative VTE rates and bleeding complications,1 the rela-
tionship between extent of hepatectomy or its surrogate, longer
operative time, and the development of major complications
should be emphasized. In general, these patients are at greatest
risk for any post-hepatectomy complication, not just VTE. For
example, patients undergoing right or extended hepatectomies are
almost twice as likely to experience bile leak and more than twice
as likely to have aVTE event in comparison with those undergoing
partial or left hepatectomies. They happen to also be most likely to
require reoperation. Combined, these associated risk factors are
likely to create a biological prothrombotic state which explains the
observed increase in VTE risk, the underlying mechanisms of
which are beyond the scope of this clinical database-driven study.
These patients would be predicted to benefit the most from
routine postoperative VTE chemoprophylaxis. The next question
to resolve concerns whether they would benefit from extended
Table 2 Rates of and independent factors associated with early versus late venous thromboembolism (VTE)
Risk factor Any VTE Early VTE Early VTE Late VTE Late VTE
OR 95% CI P-value OR 95% CI P-value
Preoperative factors
Age 75 years 3.8% 3.2% 1.92 1.19–3.10 0.007
Male 3.6% 2.7% 1.87 1.26–2.76 0.002
Intraoperative factors
Intraoperative transfusion 5.5% 4.5% 2.49 1.69–3.69 <0.001
Operative time >240 min 4.6% 3.4% 2.28 1.47–3.52 <0.001 1.2% 2.35 1.26–4.40 0.008
Postoperative factors
Organ space infection 10.0% 6.9% 2.60 1.61–4.19 <0.001 3.1% 3.78 1.87–7.66 <0.001
Return to operating room 12.5% 9.8% 3.25 1.97–5.37 <0.001 2.7% 2.84 1.27–6.33 0.011
P-values in bold indicate significance at P < 0.05.
Early, pre-discharge; late, post-discharge; OR, odds ratio; 95% CI, 95% confidence interval.
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chemoprophylaxis beyond discharge, as demonstrated in past
clinical trials.11,12,18 The present study suggests that patients who
have undergone longer operations or have suffered major compli-
cations, including OSI and ROR (both of which are high-grade
complications requiring invasive interventions), would benefit
from extended chemoprophylaxis. Given that VTE was diagnosed
at a median of 14 days post-surgery (7 days after discharge) in the
late VTE cohort, the administration of at least 14 additional days
of chemoprophylaxis from the date of discharge or until PoD 30
(whichever is later) may represent a rational recommendation
with which to start. The greatest limitation of this recommenda-
tion would concern the cost to the patient and to society, but this
should be weighed against the potential cost and prolonged
morbidity associated with each VTE event, which may range
from being asymptomatic to being completely debilitating or
life-threatening.
The major potential limitation of this study is its inability to
assess the utilization of VTE chemoprophylaxis in this NSQIP
cohort because this was not a recorded variable during the period
under study.1,19,20 Thus, it is imperative that this study be inter-
preted according to the disclosure that event rates and subsequent
analyses are based on current national practice patterns, the
granular details of which are not measured by NSQIP. Based on
historical practice patterns and published cross-sectional studies,
it would be reasonable to assume that the routine and timely use
of postoperative VTE chemoprophylaxis was not universal and
that the use of extended chemoprophylaxis was infrequent.21–23
The true, or ‘natural’, event rates for early and late VTEmay not be
exactly as reported by NSQIP. However, the scale of the national
cohort and the standardization of the definitions used allowed
for a detailed analysis of these thrombotic events, which may
occur too rarely to support evaluation with adequate power in
single-institution databases. As this is the first study to identify
hepatectomy patients who might benefit from post-discharge
VTE chemoprophylaxis, further prospective studies and cost-
effectiveness analyses are required to elucidate the true benefit of
extended VTE chemoprophylaxis after hepatectomy.
In conclusion, post-hepatectomy late VTE is a clinically distinct
entity accounting for 28.6% of all postoperative VTE. Longer
operative time, OSI (bile leaks) and ROR are independent risk
factors for late VTE. Because late VTE events occur in patients
with clearly identifiable intraoperative and postoperative risk
factors, these results provide a rationale for the selective use of
post-discharge VTE chemoprophylaxis after hepatectomy in high-
risk patients.
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